The goal of the COVER-MS study is to learn about the effects of the COVID-19 vaccines in people with MS. This is a snapshot of our findings about the vaccination side effects and reactions experienced by our participants.

**Main finding:** The frequency of vaccination reactions reported in COVER-MS was very similar to that reported in the COVID-19 vaccine clinical trials.

Which COVER-MS participants were more likely to experience reactions?
- Younger people
- Women
- Those with a prior COVID-19 infection
- Those who had a reaction after the 1st shot

What factors did not correlate with reactions?
- Whether someone was on a disease-modifying therapy or not
- Participants’ type of MS or how long they had had MS

**Participants included in this analysis: 719**

**Sex**
- Female: 15%
- Male: 85%

**MS Type**
- RRMS: 70%
- SPMS: 18%
- PPMS: 9%
- CIS/RIS: 2%

**MS Disease-modifying therapies used**
- B-Cell Depleting DMTs: 25%
- All Other DMTs: 27%
- No DMT: 48%

Average age: 53 years
Race: White 94%, All others 6%
Ethnicity: Latinx 5%, Non-Latinx 95%

We thank our participants for making this study possible. To enroll in COVER-MS, please join the iConquerMS community at [www.iConquerMS.org](http://www.iConquerMS.org). Email info@iConquerMS.org for more information.